烟雾病与IL-1β、VEGF、TGF-β1的相关性研究及临床意义
Study on the Correlation between Moyamoya Disease and IL-1β, VEGF, TGF-β1 and Clinical Significance
DOI: 10.12677/ACM.2022.1281030, PDF,   
作者: 钟家伟：济宁医学院临床医学院，山东 济宁；冯 雷*：济宁市第一人民医院神经外科，山东 济宁
关键词: 烟雾病；病理学特征；脑血管疾病；IL-1β；VEGF；TGF-β1；
摘要: 烟雾病(Moyamoya Disease)是一种极为少见的进行性脑血管疾病，是以颈内动脉末端及其主要分支进行性狭窄为主要表现，日语中的“moyamoya”一词的意思是“一股朦胧的烟雾”，指的是脑血管造影中侧支血管的特征性外观像一团烟雾。颈内动脉终末的进行性狭窄和闭塞是烟雾病病理的主要特征，并伴有侧支血管的形成。尽管进行了广泛的研究，但MMD的发病机制尚不清楚。慢性炎症是各种疾病的病理特征；炎症反应通过增殖引起内膜血管平滑肌细胞增生和新生血管通过内皮细胞增殖导致管腔狭窄和侧支形成。本文就烟雾病的病理学和IL-1β、VEGF、TGF-β1等细胞因子等作一综述和总结。
Abstract: Moyamoya disease is an extremely rare progressive cerebrovascular disease that is characterized by progressive stenosis of the terminal internal carotid artery and its major branches. The Japanese word “moyamoya” means “a hazy smoke”, referring to the characteristic appearance of the collateral vessels as a cloud of smoke on cerebral angiography. Progressive stenosis and occlusion of the end of the internal carotid artery are the main features of Moyamoya Disease pathology, along with the formation of collateral vessels. Despite extensive studies, the pathogenesis of MMD is unknown. Chronic inflammation is a pathological feature of various diseases. The inflammatory response causes endothelial vascular smooth muscle cell proliferation through proliferation and neovascu-larization through endothelial cell proliferation leading to luminal stenosis and collateral branch formation. This article provides a review and summary of the pathology of Moyamoya Disease and cytokines such as IL-1β, VEGF, and TGF-β1.
文章引用：钟家伟, 冯雷. 烟雾病与IL-1β、VEGF、TGF-β1的相关性研究及临床意义[J]. 临床医学进展, 2022, 12(8): 7142-7148. https://doi.org/10.12677/ACM.2022.1281030

参考文献

[1] Espert, R., Gadea, M., Alino, M., et al. (2018) Moyamoya Disease: Clinical, Neuroradiological, Neuropsychological and Genetic Perspective. Revue Neurologique, 66, S57-S64.
[2] 孙宁, 马骁, 魏中南, 等. 儿童烟雾病的治疗进展[J]. 中国现代医药杂志, 2021, 23(6): 105-108.
[3] Hu, J., Luo, J. and Chen, Q. (2017) The Susceptibility Pathogenesis of Moyamoya Disease. World Neurosurgery, 101, 731-741. [Google Scholar] [CrossRef] [PubMed]
[4] Kuroda, S. and Houkin, K. (2008) Moyamoya Disease: Current Concepts and Future Perspectives. The Lancet Neurology, 7, 1056-1066. [Google Scholar] [CrossRef] 
[5] Torazawa, S., Miyawaki, S., Shinya, Y., et al. (2020) De Novo Development of Moyamoya Disease after Stereotactic Radiosurgery for Brain Arteriovenous Malfor-mation in a Patient with RNF213 p.Arg4810Lys (rs112735431). World Neurosurgery, 140, 276-282. [Google Scholar] [CrossRef] [PubMed]
[6] Shang, S., Zhou, D., Ya, J., et al. (2020) Progress in Moyamoya Disease. Neurosurgical Review, 43, 371-382. [Google Scholar] [CrossRef] [PubMed]
[7] Tan, C., Niu, H., Duan, R., et al. (2019) Abnormal Embryonic Development of Cerebral Arteries as a Potential Cause of Moyamoya Disease. World Neurosurgery, 129, e224-e232. [Google Scholar] [CrossRef] [PubMed]
[8] Bersano, A., Guey, S., Bedini, G., et al. (2016) Research Pro-gresses in Understanding the Pathophysiology of Moyamoya Disease. Cerebrovascular Diseases, 41, 105-118. [Google Scholar] [CrossRef] [PubMed]
[9] Kang, H.S., Kim, J.H., Phi, J.H., et al. (2010) Plasma Matrix Metallopro-teinases, Cytokines and Angiogenic Factors in Moyamoya Disease. Journal of Neurology, Neurosurgery and Psychiatry, 81, 673-678. [Google Scholar] [CrossRef] [PubMed]
[10] Sakamoto, S., Kiura, Y., Yamasaki, F., et al. (2008) Expression of Vascular Endothelial Growth Factor in Dura Mater of Patients with Moyamoya Disease. Neurosurgical Review, 31, 77-81. [Google Scholar] [CrossRef] [PubMed]
[11] Jeon, J.S., Ahn, J.H., Moon, Y.J., et al. (2014) Expression of Cellular Retinoic Acid-Binding Protein-I (CRABP-I) in the Cerebrospinal Fluid of Adult Onset Moyamoya Disease and Its Association with Clinical Presentation and Postoperative Haemodynamic Change. Journal of Neurology, Neuro-surgery and Psychiatry, 85, 726-731. [Google Scholar] [CrossRef] [PubMed]
[12] Nanba, R., Kuroda, S., Ishikawa, T., et al. (2004) Increased Ex-pression of Hepatocyte Growth Factor in Cerebrospinal Fluid and Intracranial Artery in Moyamoya Disease. Stroke, 35, 2837- 2842. [Google Scholar] [CrossRef] 
[13] Han, Z., Li, L., Liu, P., et al. (2020) Metabolic Ad-justments by LncRNAs in Peripheral Neutrophils Partly Account for the Complete Compensation of Asymptomatic MMD Patients. CNS & Neurological Disorders—Drug Targets, 19, 306-317. [Google Scholar] [CrossRef] [PubMed]
[14] Yamamoto, M., Aoyagi, M., Tajima, S., et al. (1997) Increase in Elastin Gene Expression and Protein Synthesis in Arterial Smooth Muscle Cells Derived from Patients with Moyamoya Disease. Stroke, 28, 1733-1738. [Google Scholar] [CrossRef] 
[15] Bedini, G., Blecharz, K.G., Nava, S., et al. (2016) Vasculogenic and Angiogenic Pathways in Moyamoya Disease. Current Medicinal Chemistry, 23, 315-345. [Google Scholar] [CrossRef] [PubMed]
[16] Weinberg, D.G., Arnaout, O.M., Rahme, R.J., et al. (2011) Moyamoya Disease: A Review of Histopathology, Biochemistry, and Genetics. Neurosurgical Focus, 30, E20.
[17] Yamashita, M., Oka, K. and Tanaka, K. (1984) Cervico-Cephalic Arterial Thrombi and Thromboemboli in Moyamoya Disease—Possible Correlation with Progressive Intimal Thickening in the Intracranial Major Arteries. Stroke, 15, 264-270. [Google Scholar] [CrossRef] 
[18] Houkin, K., Yoshimoto, T., Abe, H., et al. (1998) Role of Basic Fi-broblast Growth Factor in the Pathogenesis of Moyamoya Disease. Neurosurgical Focus, 5, e2.
[19] Huang, S., Guo, Z.N., Shi, M., et al. (2017) Etiology and Pathogenesis of Moyamoya Disease: An Update on Disease Prevalence. Inter-national Journal of Stroke, 12, 246-253. [Google Scholar] [CrossRef] [PubMed]
[20] Parray, T., Martin, T.W. and Siddiqui, S. (2011) Moyamoya Disease: A Review of the Disease and Anesthetic Management. Journal of Neuro-surgical Anesthesiology, 23, 100-109. [Google Scholar] [CrossRef] 
[21] Hojo, M., Hoshimaru, M., Miyamoto, S., et al. (1998) Role of Transforming Growth Factor-beta1 in the Pathogenesis of Moyamoya Disease. Journal of Neurosurgery, 89, 623-629. [Google Scholar] [CrossRef] [PubMed]
[22] Han, W., Jin, F., Zhang, H., et al. (2020) Association of Brain-Gut Peptides with Inflammatory Cytokines in Moyamoya Disease. Mediators of Inflammation, 2020, Article ID: 5847478. [Google Scholar] [CrossRef] [PubMed]
[23] Yamamoto, M., Aoyagi, M., Fukai, N., et al. (1999) Increase in Prostaglandin E(2) Production by Interleukin-1beta in Arterial Smooth Muscle Cells Derived from Patients with Moyamoya Disease. Circulation Research, 85, 912-918. [Google Scholar] [CrossRef] 
[24] Bamforth, S.D., Lightman, S.L. and Greenwood, J. (1997) Inter-leukin-1 Beta-Induced Disruption of the Retinal Vascular Barrier of the Central Nervous System Is Mediated through Leukocyte Recruitment and Histamine. The American Journal of Pathology, 150, 329-340.
[25] Shinkaruk, S., Bayle, M., Laïn, G., et al. (2003) Vascular Endothelial Cell Growth Factor (VEGF), an Emerging Target for Cancer Chemo-therapy. Current Medicinal Chemistry—Anti-Cancer Agents, 3, 95-117. [Google Scholar] [CrossRef] [PubMed]
[26] He, J., Wang, R., Zhang, D., et al. (2014) Expression of Circulat-ing Vascular Endothelial Growth Factor-Antagonizing Cytokines and Vascular Stabilizing Factors Prior to and Following Bypass Surgery in Patients with Moyamoya Disease. Experimental and Therapeutic Medicine, 8, 302-308. [Google Scholar] [CrossRef] [PubMed]
[27] Rosenstein, J.M., Mani, N., Silverman, W.F., et al. (1998) Patterns of Brain Angiogenesis after Vascular Endothelial Growth Factor Administration in Vitro and in Vivo. Proceedings of the National Academy of Sciences of the United States of America, 95, 7086-7091. [Google Scholar] [CrossRef] [PubMed]
[28] Shima, D.T., Adamis, A.P., Ferrara, N., et al. (1995) Hypoxic Induc-tion of Endothelial Cell Growth Factors in Retinal Cells: Identification and Characterization of Vascular Endothelial Growth Factor (VEGF) as the Mitogen. Molecular Medicine, 1, 182-193. [Google Scholar] [CrossRef] 
[29] Cobbs, C.S., Chen, J., Greenberg, D.A., et al. (1998) Vascular Endothe-lial Growth Factor Expression in Transient Focal Cerebral Ischemia in the Rat. Neuroscience Letters, 249, 79-82. [Google Scholar] [CrossRef] 
[30] Blecharz-Lang, K.G., Prinz, V., Burek, M., et al. (2018) Ge-latinolytic Activity of Autocrine Matrix Metalloproteinase-9 Leads to Endothelial De-Arrangement in Moyamoya Disease. Journal of Cerebral Blood Flow & Metabolism, 38, 1940-1953. [Google Scholar] [CrossRef] 
[31] 刘超. 转化生长因子B1单核苷酸多态性与烟雾病的相关性研究[D]: [博士学位论文]. 长春: 吉林大学, 2012.
[32] 苗军, 刘少云, 崔松, 等. 脑出血患者外周血及脑组织中IL-17、TGF-β的表达及意义[J]. 脑与神经疾病杂志, 2017, 25(7): 426-428.
[33] 陈捷, 程亚玲, 陈海燕, 等. 成年烟雾病患者血清血管细胞黏附分子1、基质金属蛋白酶9、转化生长因子β、血管内皮生长因子水平变化及其临床意义研究[J]. 实用心脑肺血管病杂志, 2020, 28(5): 27-33.
[34] Ueno, M., Kira, R., Matsushima, T., et al. (2000) Moyamoya Disease and Transforming Growth Fac-tor-beta1. Journal of Neurosurgery, 92, 907-908.
[35] Liu, C., Roder, C., Schulte, C., et al. (2012) Analysis of TGFB1 in European and Japanese Moyamoya Disease Patients. European Journal of Medical Genetics, 55, 531-534. [Google Scholar] [CrossRef] [PubMed]
[36] Roder, C., Peters, V., Kasuya, H., et al. (2010) Polymorphisms in TGFB1 and PDGFRB Are Associated with Moyamoya Disease in European Patients. Acta Neurochirurgica (Wien), 152, 2153-2160. [Google Scholar] [CrossRef] [PubMed]

为你推荐